Aroa BiosurgeryAROAF +35.24%39 3-Year ROIIC % is 75.91 as of Mar. 2026, which is 607% above its 10-year median of 10.74. GuruFocus rates AROAF with a GF Score™ of 39/100 and a GF Value™ of $0.71 (Modestly Undervalued). The stock has 1 warning sign investors should review. Among 800 Medical Devices & Instruments companies, Aroa Biosurgery ranks better than 86.87% on this metric.
3-Year Return on Invested Incremental Capital (3-Year ROIIC %) measures the change in earnings as a percentage of change in investment over 3-year.
Aroa Biosurgery's 3-Year ROIIC % for the quarter that ended in Mar. 2026 was 75.91%. High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
The industry rank for Aroa Biosurgery's 3-Year ROIIC % or its related term are showing as below:
AROAF's 3-Year ROIIC % is ranked better than 86.87% of 800
companies
in the Medical Devices & Instruments industry
Industry Median: 1.285
vs AROAF: 75.91
Return on Incremental Invested Capital (ROIIC) is an extension of Return on Investment Capital (ROIC). ROIC % tells investors how efficiently that profitability is earned per dollar of company capital. ROIIC narrows the focus even further and shows how profitable each additional unit of capital investment could be. ROIIC % is a more powerful metric than ROIC because it measures how much money the company can generate going forward on future capital investments.
High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
Be Aware
It's important to keep in mind that when tracking ROIIC, the metric is better suited to forecasting the trend of future returns rather than measuring current return on investment.
Aroa Biosurgery 3-Year ROIIC % Related Terms
Aroa Biosurgery 3-Year ROIIC % Historical Data
* Premium members only.
The historical data trend for Aroa Biosurgery's 3-Year ROIIC % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, Aroa Biosurgery's 3-Year ROIIC %, along with its competitors' market caps and 3-Year ROIIC % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Aroa Biosurgery 3-Year ROIIC % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Aroa Biosurgery's 3-Year ROIIC % distribution charts can be found below:
* The bar in red indicates where Aroa Biosurgery's 3-Year ROIIC % falls into.
Aroa Biosurgery's 3-Year ROIIC % for the quarter that ended in Mar. 2026 is calculated as:
3-Year ROIIC %
=
3-Year Incremental Net Operating Profit After Taxes (NOPAT)**
/
3-Year Incremental Invested Capital**
=
( -0.323828 (Mar. 2026) - -5.427 (Mar. 2023) )
/
( 51.087 (Mar. 2026) - 41.854 (Mar. 2023) )
=
5.103172
/
9.233
=
55.27%***
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
** Annual data of NOPAT and Invested Capital was used to calculate 3-Year ROIIC %.
*** Please be aware that the ROIIC (Return on Invested Capital) calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.
Aroa Biosurgery (AROAF) has a 3-Year ROIIC % of 75.91 as of Mar. 2026. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on Aroa Biosurgery and its competitors. This is 607% above median its historical median of 10.74. According to the industry distribution chart, Aroa Biosurgery ranks #105 out of 800 companies in the Medical Devices & Instruments industry, placing it in the top 13.1%.
Is Aroa Biosurgery's 3-Year ROIIC % too high?
Aroa Biosurgery's current 3-Year ROIIC % of 75.91 is 607% above median its 10-year median of 10.74. The Medical Devices & Instruments industry median 3-Year ROIIC % is 1.29. Aroa Biosurgery's value of 75.91 is 5807.4% above this industry median. Based on the distribution chart, Aroa Biosurgery ranks #105 out of 800 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Aroa Biosurgery has a GF Score™ of 39/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Aroa Biosurgery's 3-Year ROIIC % compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Aroa Biosurgery ranks #105 out of 800 companies for 3-Year ROIIC %. This places Aroa Biosurgery in the top 13% of its industry — outperforming the majority of peers. The industry median 3-Year ROIIC % is 1.29. Aroa Biosurgery's value of 75.91 is 5807.4% above this benchmark. While the company's 10-year median is 10.74 vs. the industry median of 1.29, Aroa Biosurgery has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year ROIIC % for a Medical Devices & Instruments company?
The median 3-Year ROIIC % among Medical Devices & Instruments companies is 1.29, based on 800 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year ROIIC % significantly above this median, while those in the bottom quartile fall well below. However, 3-Year ROIIC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Aroa Biosurgery's current 3-Year ROIIC % of 75.91 is 5807.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year ROIIC % mean?
A high 3-Year ROIIC % can signal that a stock is expensive relative to its fundamentals. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on Aroa Biosurgery and its competitors. For the Medical Devices & Instruments industry, the median 3-Year ROIIC % is 1.29 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Aroa Biosurgery's current 3-Year ROIIC % is 75.91, which is 607% above median its own 10-year median of 10.74. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Aroa Biosurgery stock overvalued right now?
Based on GuruFocus' analysis, Aroa Biosurgery (AROAF) is currently considered Modestly Undervalued. The stock's GF Value™ is $0.71, compared to a current price of $0.52 — trading 26.8% below its estimated fair value. The current 3-Year ROIIC % is 75.91, which is 607% above median its 10-year median of 10.74 and 5807.4% above the Medical Devices & Instruments industry median of 1.29. Aroa Biosurgery's overall GF Score™ is 39/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year ROIIC % calculated?
3-Year ROIIC % is calculated from a company's financial statements. For Aroa Biosurgery (AROAF), the current 3-Year ROIIC % is 75.91 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Aroa Biosurgery (AROAF) Overvalued in 2026?
Based on GuruFocus' analysis, Aroa Biosurgery stock appears to be undervalued.
The current stock price of $0.52 is trading 26.8% below its estimated GF Value™ of $0.71.
GuruFocus considers Aroa Biosurgery to be Modestly Undervalued.
Key valuation signals for AROAF:
3-Year ROIIC %: 75.91 (607% above median its 10-year median of 10.74)
GF Value™: $0.71 vs. price of $0.52 (26.8% below fair value)
Industry Position: 5807.4% above the Medical Devices & Instruments median (#105 of 800)
No single metric tells the full story. See the AROAF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Aroa Biosurgery Ltd is a soft tissue regeneration company that develops, manufactures, and sells medical devices for wound and soft tissue repair using its proprietary extracellular matrix (ECM) technology. It is focused on improving the rate and quality of healing in complex wounds and soft tissue reconstruction. The company is in the business of developing, manufacturing, and selling soft tissue repair products. The company's principal market is the United States, where it has five key products for sale targeting chronic wounds, hernia, plastics, reconstructive surgery, and trauma/limb salvage/tumor surgery.
39GF Score
Get the complete analysis for AROAF
3-Year ROIIC % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
AROAF has been successfully added to your 
